Litcius/Paper detail

Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients

Levi B. Richards, Job J.M.H. van Bragt, Reim Aarab, Cristina Longo, Anne H. Neerincx, Jaap K. Sont, Els J.M. Weersink, Gert‐Jan Braunstahl, Anneke Ten Brinke, Elisabeth H. Bel, Anke H. Maitland‐van der Zee

2020The Journal of Allergy and Clinical Immunology In Practice19 citationsDOIOpen Access PDF

Topics & Concepts

MepolizumabMedicineAsthmaPrednisonePopulationDoseClinical trialInclusion and exclusion criteriaPediatricsInternal medicineRandomized controlled trialPhysical therapyEosinophilAlternative medicinePathologyEnvironmental healthAsthma and respiratory diseasesDelphi Technique in ResearchIL-33, ST2, and ILC Pathways
Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients | Litcius